Gilead, GlobeImmune team up on HBV vaccines

Gilead Sciences ($GILD) is giving GlobeImmune an undisclosed upfront payment for early development and funding to support continued development of its hepatitis B virus (HBV) therapeutic vaccine program. The two developers have inked a worldwide license and collaboration agreement for vaccine products for use in conjunction with Gilead's Viread, which is indicated to treat HIV/AIDS, and other oral therapies for the treatment of chronic HBV infection. Release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.